Multiple purchasing bodies weaken the state’s bargaining power
LIBYA – Ahmed Al-Naqeeq, a member of the Joint Higher Committee for Implementing the Strategic Cooperation Plan to Combat Corruption between the Audit Bureau and the National Anti-Corruption Commission, has said drug purchasing moved from a single central body in 2022 to more than 25 bodies in 2025, which he said has scattered spending, led to price disparities and weakened the state’s bargaining power.
Estimated increases not tied to actual consumption
In exclusive comments to the Al Jazeera Net website, Al-Naqeeq said estimates of drug requirements are based on the previous year’s data, with estimated increases of between 10% and 15%, without being adequately linked to actual consumption and available stock.
He added that the review found some items whose quantities exceeded requirements and others that fell short, as well as letters of credit that were cancelled after contracts were awarded and others that remained open, as part of what he described as flaws in estimating requirements and managing drug procurement.
